{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:53Z","timestamp":1787071193673,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antimoniate compounds have been used as gold standard treatment for cutaneous leishmaniasis since many years ago, but with increase in incidence of drug as well as individual contraindications, more attention has been given to alternative treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy of intralesional amphotericin B as an alternative treatment for cutaneous leishmaniasis in Mashhad, Iran, during 2007-2009.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Non-random sampling from both sexes and without any age limitation of cases eligible for this alternative treatment was done. Size and induration of lesions were measured before beginning and weakly during the treatment. Amphotericin B (2 mg\/ml) was injected into lesions weekly for up to 12 weeks and the cases were followed up for the treatment responses, possible side effects and recurrence of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 93 patients with a mean age of 20.81 \u00b1 15.26 years were included in this study. At the end of 12\n                      <jats:sup>th<\/jats:sup>\n                      week, 61.4% of the patients were recovered completely (more than 90% reduction in size and induration), 21.6% had partial remission (60-90% reduction in size and induration), and 17% had less than 60% reduction in size and induration of skin lesions. Injection side effects were insignificant and did not lead to premature discontinuation of treatment in any patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Weekly intralesional injection of amphotericin B looks promising, considering the fact that most of the patients in this study were resistant to antimoniates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0019-5154.143571","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T03:05:15Z","timestamp":1414551915000},"page":"631-631","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis"],"prefix":"10.4103","volume":"59","author":[{"given":"Vahid Mashayekhi","family":"Goyonlo","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Vosoughi","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Kiafar","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Nahidi","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Momenzadeh","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Taheri","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Cutaneous Leishmaniasis Research Center, School of Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","first-page":"1","article-title":"Cutaneous leishmaniasis of the Old World","volume":"8","author":"Alrajhi","year":"2003","journal-title":"Skin Ther Lett"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clind\/24.4.684","article-title":"Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years","volume":"24","author":"Berman","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4269\/ajtmh.1989.41.687","article-title":"A review of the geographic distribution and epidemiology of leishmaniasis in the new word","volume":"41","author":"Grimaldi","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: Current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbial Infect Dis"},{"key":"R5-20250921","first-page":"538","article-title":"Topical treatment for cutaneous leishmaniasis","volume":"3","author":"Garnier","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0035-9203(01)90223-8","article-title":"The increase in risk factors for leishmaniasis worldwide","volume":"95","author":"Desjeux","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4269\/ajtmh.2001.65.27","article-title":"Assessment of Leishmaniasis notification system in Santiago del Estero, Argentina, 1990-1993","volume":"65","author":"Yad\u00f3n","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 1","key":"R8-20250921","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1179\/000349803225002516","article-title":"HIV and transmission of leishmania","volume":"97","author":"Molina","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microb Rev"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4269\/ajtmh.2011.10-0002","article-title":"Systemic meglumine antimoniate in acute cutaneous leishmaniasis: Children versus adults","volume":"84","author":"Layegh","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"R14-20250921","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4269\/ajtmh.1989.40.159","article-title":"Biochemistry of Pentostam resistant leishmania","volume":"40","author":"Berman","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-4362.1996.tb03669.x","article-title":"Cutaneous leishmaniasis: Schedules for intralesional treatment with sodium stibogluconate","volume":"35","author":"Tallab","year":"1996","journal-title":"Int J Dermatol"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-4632.2006.02822.x","article-title":"Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis","volume":"45","author":"Salmanpour","year":"2006","journal-title":"Int J Dermatol"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/AAC.49.8.3274-3280.2005","article-title":"Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana","volume":"49","author":"Al-Mohammed","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250921","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr Pharm"},{"key":"R19-20250921","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.1995.52.536","article-title":"Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India","volume":"52","author":"Jha","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"R20-20250921","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","article-title":"A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): A pilot study","volume":"17","author":"Thakur","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"R22-20250921","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.42.12.3092","article-title":"Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B","volume":"42","author":"Frankenburg","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20250921","first-page":"91","article-title":"Amphotericin B therapy in kala-azar","volume":"91","author":"Giri","year":"1993","journal-title":"J Indian Med Assoc"},{"key":"R24-20250921","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1378\/chest.100.3.783","article-title":"Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen","volume":"100","author":"Aerdts","year":"1991","journal-title":"Chest"},{"key":"R25-20250921","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00005537-199611000-00005","article-title":"Antifungal activity against allergic fungal sinusitis organisms","volume":"106","author":"Bent","year":"1996","journal-title":"Laryngoscope"},{"key":"R26-20250921","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archderm.135.7.856","article-title":"Topical amphotericin B for cutaneous Leishmaniasis","volume":"135","author":"Vardy","year":"1999","journal-title":"Arch Dermatol"},{"key":"R27-20250921","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Liposomal Amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"R28-20250921","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R29-20250921","first-page":"656523","article-title":"Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the treatment of cutaneous Leishmaniasis","author":"Layegh","year":"2011","journal-title":"J Parasitol Res 2011"},{"key":"R30-20250921","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1365-4632.2010.04523.x","article-title":"Treatment of acute cutaneous leishmaniasis whit intralesional injection of meglumine antimoniate: Comparison of conventional technique with mesotherapy gun","volume":"49","author":"Kashani","year":"2010","journal-title":"Int J Dermatol"},{"key":"R31-20250921","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-4632.2009.03971.x","article-title":"Systematic review of New World cutaneous leishmaniasis: Several points","volume":"48","author":"Khatami","year":"2009","journal-title":"Int J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201459060-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:52Z","timestamp":1787067772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201459060-00037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-5154.143571","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2013-10-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}